Swiss pharmaceutical company Novartis has published pre-specified interim analysis results from the Phase III APPLAUSE-IgAN clinical trial of Fabhalta (iptacopan) in Immunoglobulin A nephropathy (IgAN) patients.
The randomised, placebo-controlled trial enrolled 518 adult patients with primary IgAN, who were given two oral doses of Fabhalta a day.
Go deeper with GlobalData
The primary endpoint of the interim analysis is proteinuria reduction at nine months based on the urine protein to creatinine ratio (UPCR), while the final analysis has the annualised total eGFR slope over 24 months as its primary endpoint.
Various other secondary endpoints, including the proportion of participants reaching UPCR <1g/g without receiving other treatments, will also be evaluated in the final analysis.
The interim data indicated that subjects treated with Fabhalta attained a significant 38.3% decline in proteinuria versus placebo, in addition to supportive care.
Treatment with Fabhalta was well-tolerated, with its safety profile in line with prior data.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataData from the primary endpoint for final analysis is expected next year.
Novartis cardiovascular, renal and metabolism development unit global head David Soergel said: “IgAN progresses over many years, and patients’ needs may evolve such that different therapies may be best used at different times.
“Our renal pipeline includes medicines with a variety of mechanisms which may allow them to be targeted to patients based on their clinical characteristics.”
Fabhalta is an investigational Factor B inhibitor of the alternative complement pathway.
The drug was approved by the US Food and Drug Administration (FDA) for adult patients with paroxysmal nocturnal haemoglobinuria (PNH) in December last year.
Last month, it also received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).
In October last year, Novartis reported positive data from a Phase III clinical trial of atrasentan in IgAN patients.
